8-K: Coherus Regains Nasdaq Compliance, Averting Delisting

Coherus Oncology, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously disclosed deficiency notice.

Summary

• Coherus Oncology, Inc. received a deficiency notice from Nasdaq on June 30, 2025, because its common stock bid price closed below $1.00 per share for 30 consecutive business days.
• The company had 180 calendar days, until December 29, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
• On September 5, 2025, Nasdaq notified the company that its common stock closing price was $1.00 or greater for the requisite period.
• The company has now regained full compliance with Listing Rule 5550(a)(2) and all continued listing standards of the Nasdaq Global Market, and the matter is closed.

Sentiment

Score: 8

Explanation: The company successfully resolved a Nasdaq listing deficiency, removing a significant overhang and potential delisting risk, which is a strong positive for stability and investor confidence.

Positives

• Regained full compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)).
• Avoided potential delisting from the Nasdaq Global Market.
• The previously disclosed deficiency notice matter is now officially closed by Nasdaq.
• Currently in full compliance with all Nasdaq continued listing standards.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing beyond the resolution of the compliance issue.

Industry Context

Regaining compliance with minimum bid price requirements is a common challenge for smaller or developing biotechnology companies. Successful resolution, as seen here, removes a significant regulatory overhang and allows the company to focus on its core business without the immediate threat of delisting, which can impact investor confidence and access to capital.

Stakeholder Impact

• Shareholders: Reduced risk of delisting, which can stabilize the stock price and maintain liquidity on a major exchange.
• Employees: Increased job security and stability due to the company's continued listing on Nasdaq.
• Creditors: Improved perception of the company's financial and operational stability, potentially easing future financing terms.

Key Dates

Recommendation

The company successfully resolved a Nasdaq listing deficiency, which removes a significant overhang and potential delisting risk. This is a positive development for stability but does not inherently signal new growth or fundamental improvements in the business that would warrant a 'buy' recommendation. Investors should 'hold' while monitoring for future operational performance.

Keywords

Coherus Oncology, CHRS, Nasdaq compliance, minimum bid price, delisting risk, biotechnology, pharmaceuticals, regulatory compliance